Ultragenyx Pharmaceutical Inc.’s Price-to-Sales Ratio at a glance
Ultragenyx Pharmaceutical Inc. reports price-to-sales ratio of 6.8x for Dec 2024. The prior period recorded 8.1x (Dec 2023). Year over year the metric moved −1.3 (−16.1%). The rolling three-period average stands at 7.9x. Data last refreshed Dec 7, 2025, 2:56 AM.
Latest reading
6.8x · Dec 2024
YoY movement
−1.3 (−16.1%)
Rolling average
7.9x
Current Price-to-Sales Ratio
6.8x
−1.3
−16.1%
Rolling average
7.9x
Latest Value
6.8x
Dec 2024
YoY Change
−1.3
Absolute
YoY Change %
−16.1%
Rate of change
3-Period Avg
7.9x
Smoothed
Narrative signal
Ultragenyx Pharmaceutical Inc.’s price-to-sales ratio stands at 6.8x for Dec 2024. Year-over-year, the metric shifted by −1.3, translating into a −16.1% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How price-to-sales ratio shapes Ultragenyx Pharmaceutical Inc.'s story
As of Dec 2024, Ultragenyx Pharmaceutical Inc. reports price-to-sales ratio of 6.8x. Track price-to-sales multiples to contextualize revenue-driven valuation swings and peer comparisons.
When to use price-to-sales
P/S is helpful for companies with slim or volatile profits. It shows how rich investors value each dollar of revenue.
Compare against industry norms
High-growth software firms command higher P/S ratios than retailers. Stack the metric versus sector averages to read sentiment.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
86.3%
Operating Margin
-95.7%
Net Profit Margin
-101.6%
Return on Equity
-222.9%
Return on Assets
-37.9%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Ultragenyx Pharmaceutical Inc. (RARE) FAQs
Answers tailored to Ultragenyx Pharmaceutical Inc.’s price-to-sales ratio profile using the latest Financial Modeling Prep data.
What is Ultragenyx Pharmaceutical Inc.'s current price-to-sales ratio?
As of Dec 2024, Ultragenyx Pharmaceutical Inc. reports price-to-sales ratio of 6.8x. This reading reflects the latest filings and price data for RARE.
How is Ultragenyx Pharmaceutical Inc.'s price-to-sales ratio trending year over year?
Year-over-year, the figure shifts by −1.3 (−16.1%). Pair this context with revenue growth and free cash flow signals to gauge momentum for RARE.
Why does price-to-sales ratio matter for Ultragenyx Pharmaceutical Inc.?
Price-to-sales compares market capitalization with revenue to assess valuation against top-line performance. For Ultragenyx Pharmaceutical Inc., operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Ultragenyx Pharmaceutical Inc.'s price-to-sales ratio above its recent average?
Ultragenyx Pharmaceutical Inc.'s rolling three-period average sits at 7.9x. Comparing the latest reading of 6.8x to that baseline highlights whether momentum is building or fading for RARE.
How frequently is Ultragenyx Pharmaceutical Inc.'s price-to-sales ratio refreshed?
Data for RARE was last refreshed on Dec 7, 2025, 2:56 AM and updates automatically every 24 hours, keeping your valuation inputs current.